Stock Track | CSPC Pharma Plummets 12.82% Intraday Following AstraZeneca Collaboration Announcement

Stock Track

Jan 30

CSPC Pharmaceutical Group's stock plummeted 12.82% during intraday trading on Friday after the company disclosed a major strategic partnership.

The Hong Kong-listed firm announced it has entered into a collaboration and license agreement with global pharmaceutical giant AstraZeneca for the development of innovative long-acting peptide medicines. The deal grants AstraZeneca exclusive global rights outside mainland China, Hong Kong, Macau, and Taiwan to CSPC's once-monthly injectable weight management portfolio, which includes one clinical-stage asset and three preclinical programs.

While CSPC is set to receive a significant upfront payment of $1.2 billion and is eligible for substantial future milestone payments—up to $3.5 billion for development and up to $13.8 billion for sales—along with double-digit royalties on net sales, the market's immediate reaction was sharply negative. This suggests investor concerns may center on the long-term strategic value of licensing out these potentially valuable assets or on the specific financial terms of the agreement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1164193181"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1164193181\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1164193181?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-30 12:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164193181","market":"sg","top_or_hot":-1,"title":"Stock Track | CSPC Pharma Plummets 12.82% Intraday Following AstraZeneca Collaboration Announcement","media":"Stock Track","content":"<p>CSPC Pharmaceutical Group's stock plummeted 12.82% during intraday trading on Friday after the company disclosed a major strategic partnership.</p><p>The Hong Kong-listed firm announced it has entered into a collaboration and license agreement with global pharmaceutical giant AstraZeneca for the development of innovative long-acting peptide medicines. The deal grants AstraZeneca exclusive global rights outside mainland China, Hong Kong, Macau, and Taiwan to CSPC's once-monthly injectable weight management portfolio, which includes one clinical-stage asset and three preclinical programs.</p><p>While CSPC is set to receive a significant upfront payment of $1.2 billion and is eligible for substantial future milestone payments—up to $3.5 billion for development and up to $13.8 billion for sales—along with double-digit royalties on net sales, the market's immediate reaction was sharply negative. This suggests investor concerns may center on the long-term strategic value of licensing out these potentially valuable assets or on the specific financial terms of the agreement.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CSPC Pharma Plummets 12.82% Intraday Following AstraZeneca Collaboration Announcement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CSPC Pharma Plummets 12.82% Intraday Following AstraZeneca Collaboration Announcement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-01-30 12:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSPC Pharmaceutical Group's stock plummeted 12.82% during intraday trading on Friday after the company disclosed a major strategic partnership.</p><p>The Hong Kong-listed firm announced it has entered into a collaboration and license agreement with global pharmaceutical giant AstraZeneca for the development of innovative long-acting peptide medicines. The deal grants AstraZeneca exclusive global rights outside mainland China, Hong Kong, Macau, and Taiwan to CSPC's once-monthly injectable weight management portfolio, which includes one clinical-stage asset and three preclinical programs.</p><p>While CSPC is set to receive a significant upfront payment of $1.2 billion and is eligible for substantial future milestone payments—up to $3.5 billion for development and up to $13.8 billion for sales—along with double-digit royalties on net sales, the market's immediate reaction was sharply negative. This suggests investor concerns may center on the long-term strategic value of licensing out these potentially valuable assets or on the specific financial terms of the agreement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1164193181","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164193181","pubTimestamp":1769746751,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"CSPC Pharmaceutical Group's stock plummeted 12.82% during intraday trading on Friday after the company disclosed a major strategic partnership.The Hong Kong-listed firm announced it has entered into...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"个股轨迹|阿斯利康宣布合作石药盘中暴跌12.82%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"CSPC Pharmaceutical Group's stock plummeted 12.82% during intraday trading on Friday after the company disclosed a major strategic partnership.The Hong Kong-listed firm announced it has entered into a collaboration and license agreement with global pharmaceutical giant AstraZeneca for the development of innovative long-acting peptide medicines. The deal grants AstraZeneca exclusive global rights outside mainland China, Hong Kong, Macau, and Taiwan to CSPC's once-monthly injectable weight management portfolio, which includes one clinical-stage asset and three preclinical programs.While CSPC is set to receive a significant upfront payment of $1.2 billion and is eligible for substantial future milestone payments—up to $3.5 billion for development and up to $13.8 billion for sales—along with double-digit royalties on net sales, the market's immediate reaction was sharply negative. This suggests investor concerns may center on the long-term strategic value of licensing out these potentially valuable assets or on the specific financial terms of the agreement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}